-
FBR Upgrades Kite Pharma, Sees 35% Upside
Tuesday, January 19, 2016 - 11:05am | 308Read More...Kite Pharma Inc (NASDAQ: KITE) shares have lost 16 percent since October 20. FBR & Co’s Ed White upgraded the rating for the company from Market Perform to Outperform, while raising the price target from $72 to $75. Kite Pharma’s impressive performance in 2015 could...
-
Here's What Wall Street Thinks Of Chimerix After The Crash
Tuesday, December 29, 2015 - 11:12am | 357Read More...Chimerix Inc (NASDAQ: CMRX) shares were crushed on Monday, as the stock fell more than 80 percent following news that its brincidofovir SUPPRESS study fell short of endpoint expectations in the prevention of cytomegalovirus (CMV) infection. After the big fall, is it time to stick a fork in Chimerix...
-
FBR Met With Juno's Management; Here's What Happened
Tuesday, October 6, 2015 - 11:54am | 292Read More...The share price of Juno Therapeutics, Inc. (NASDAQ: JUNO) has risen 20.41 percent over the past month, touching a high of $43.59 on October 5. Ed White of FBR & Co has maintained an Outperform rating on the company, with a price target of $73. Following investor meetings with the...
